111, Inc. Announces First Quarter 2023 Unaudited Financial Results

SHANGHAI,June 15,2023 --111,Inc. ("111" or the "Company") (NASDAQ: YI),a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China,today announced its unaudited financial results for the first quarter ended March 31,2023.

First Quarter 2023 Highlights

Net revenues were RMB3.7 billion (US$538.3 million),representing an increase of 23.9% year-over-year.

Gross segment profit(1) increased by 22.7% year-over-year,with B2B segment profit increasing by 25.5% year-over-year.

Total operating expenses were RMB257.9 million (US$37.6 million),compared to RMB294.7 million in the same quarter of last year. As a percentage of net revenues,total operating expenses decreased to 7.0% from 9.9% in the same quarter of last year,which reflected continuous improvement in our operation efficiency.

Loss from operationswas RMB21.7 million (US$3.2 million),compared to RMB102.2 million in the same quarter of last year. As a percentage of net revenues,loss from operations decreased to 0.6% from 3.4% in the same quarter of last year.

Non-GAAP income from operations(2)wasRMB2.5 million(US$0.4 million),compared to Non-GAAP loss from operations wasRMB72.4 millionin the same quarter of last year.

(1) Gross segment profit represents net revenues less cost of goods sold.

(2) Non-GAAP income from operations represents income from operations excluding share-based compensation expenses.

Mr. Junling Liu,Co-Founder,Chairman,and Chief Executive Officer of 111,commented,"We are pleased to report another solid quarter as well as a positive operating results at Non-GAAP level. Net revenue increased by 23.9% year-over-year to RMB3.7 billion,marking the 19th consecutive quarter of year-over-year growth for 111 since the company's NASDAQ IPO. Our gross segment profit for the quarter increased by 22.7% year-over-year. As a result,loss from operation decreased to RMB22 million compared to RMB102 million in the same quarter of last year. Non-GAAP operating profit for the quarter turned positive as compared to a Non-GAAP loss from operations in the same quarter of last year,which partially benefited from the lifting of COVID-related restrictions since December last year."

Mr. Liu added,"In addition,we continued to enhance our operation efficiency and total operating expenses as a percentage of net revenues decreased to 7.0% in this quarter from 9.9% in the same quarter of last year. We expect this momentum to continue as we scale,and meanwhile we will continue to focus on delivering best services to our customers/patients."

"These results stem from our sustained,strategic endeavors. We have enhanced partnerships with upstream pharmaceutical partners. By directly working with 500+ pharmaceutical companies,we offer value-add services to numerous enterprises,debuted products like Sanofi's Allegra on our B2C platform,while our B2B platform's digital marketing tool,"Telescope," offers invaluable market insights. Our digital empowerment to downstream pharmacies provided them with cost-effective products and operational efficiency. By the end of Q1,we served more than 435,000 retail pharmacies,with our 1 Health program engaging approximately 20,000 drugstores. Meanwhile,our operational efficiency continues to improve with various cost saving initiatives,better corporate governance,and technology investments. We've notably cut fulfillment costs through optimizing our own and joint-venture warehouses,while our new advisory department,focused on customer-centric value creation,is refining product assortment and pricing strategies."

"We believe that our efforts to achieve margin expansion,as well as to optimize our cost and improve our organizational alignment,have delivered positive results. We will keep optimizing product assortment based on customer needs,reducing costs with direct sourcing,and improve our competitiveness through intelligent pricing. We will keep improving efficiency through supply chain optimization and we will continually commit to digitization to enhance processes and drive innovation. We are confident that our strong technology capabilities will continue to enable us to build scale,deliver profitability,and maximize values for our shareholders."

First Quarter 2023 Financial Results

Net revenueswereRMB3.7 billion(US$538.3 million),representing an increase of 23.9% fromRMB3.0 billionin the same quarter of last year.

(In thousands RMB)

For the three months ended March 31,

2022

2023

YoY

B2B Net Revenue

Product

2,851,396

3,562,682

24.9%

Service

18,360

21,141

15.1%

Sub-Total

2,869,756

3,583,823

24.9%

Cost of Products Sold(3)

2,701,643

3,372,828

24.8%

Segment Profit

168,113

210,995

25.5%

Segment Profit %

5.9%

5.9%

(In thousands RMB)

For the three months ended March 31,

2022

2023

YoY

B2C Net Revenue

Product

102,131

106,608

4.4%

Service

10,704

6,330

-40.9%

Sub-Total

112,835

112,938

0.1%

Cost of Products Sold

88,413

87,720

-0.8%

Segment Profit

24,422

25,218

3.3%

Segment Profit %

21.6%

22.3%

(3) For segment reporting purposes,purchase rebates are allocated to the B2B segment and B2C segments primarily based on the amount of cost of products sold for each segment. Cost of products sold does not include other direct costs related to cost of product sales such as shipping and handling expense,payroll and benefits of logistic staff,logistic centers rental expenses and depreciation expenses,which are recorded in the fulfillment expenses. Cost of service revenue is recorded in the operating expense.

Operating costs and expenseswereRMB3.7 billion(US$541.5million),representing an increase of 20.5% fromRMB3.1 billionin the same quarter of last year.

Cost of products soldwasRMB3.5 billion(US$503.9 million),representing an increase of 24.0% fromRMB2.8 billionin the same quarter of last year. The increase was primarily due to our revenue growth in B2B business,which increased by 24.9% from the same quarter last year.

Fulfillment expenseswereRMB102.7 million(US$14.9 million),representing an increase of 8.6% fromRMB94.5 millionin the same quarter of last year. Fulfillment expenses accounted for 2.8% of net revenues this quarter as compared to 3.2% in the same quarter of last year.

Selling and marketing expenseswereRMB89.2 million(US$13.0 million),representing a decrease of 22.3% fromRMB114.9 millionin the same quarter of last year. Excluding the share-based compensation expenses of RMB1.1 million for the quarter and RMB8.4 million for the same quarter last year,respectively,selling and marketing expenses as a percentage of net revenues,accounted for 2.4% in the quarter as compared to 3.6% in the same quarter of last year.

General and administrative expenseswereRMB41.3 million(US$6.0 million),representing a decrease of 13.9% fromRMB48.0 millionin the same quarter of last year. Excluding the share-based compensation expenses of RMB19.0 million for the quarter and RMB17.7 million for the same quarter last year,general and administrative expenses as a percentage of net revenues,accounted for 0.6% in the quarter as compared to 1.0% in the same quarter of last year.

Technology expenseswereRMB25.3 million(US$3.7 million),compared withRMB39.0 millionin the same quarter of last year. Excluding the share-based compensation expenses of RMB4.1 million for the quarter and RMB3.6 million for the same quarter last year,Technology expenses as a percentage of net revenues,accounted for 0.6% in the quarter as compared to 1.2% in the same quarter of last year.

Loss from operationswasRMB21.7 million(US$3.2 million),compared toRMB102.2 millionin the same quarter of last year. As a percentage of net revenues,loss from operations decreased to 0.6% in the quarter from 3.4% in the same quarter of last year.

Non-GAAP income from operationswasRMB2.5 million(US$0.4 million),compared to Non-GAAP loss from operations wasRMB72.4 millionin the same quarter of last year.

Net losswasRMB19.4 million(US$2.8 million),compared toRMB101.0 millionin the same quarter of last year. As a percentage of net revenues,net loss decreased to 0.5% in the quarter from 3.4% in same quarter of last year.

Non-GAAP net income (4)wasRMB4.9 million(US$0.7 million),compared to Non-GAAP net loss wasRMB71.2 millionin the same quarter of last year.

Net loss attributable to ordinary shareholderswasRMB31.8 million(US$4.6 million),compared toRMB110.3 millionin the same quarter of last year. As a percentage of net revenues,net loss attributable to ordinary shareholders decreased to 0.9% in the quarter from 3.7% in same quarter of last year.

Non-GAAP net loss attributable to ordinary shareholders (5)was RMB7.6 million (US$1.1 million),compared to RMB80.6 million in the same quarter of last year. As a percentage of net revenues,non-GAAP net loss attributable to ordinary shareholders decreased to 0.2% in the quarter from 2.7% in same quarter of last year.

(4) Non-GAAP net income represents net income excluding share-based compensation expenses,net of tax. Considering the impact of accretion of redeemable non-controlling interest for the first quarter 2023,non-GAAP net income is used as a more meaningful measurement of the operation performance of the Company.

(5) Non-GAAP net loss attributable to ordinary shareholders represents net loss attributable to ordinary shareholders excluding share-based compensation expenses,net of tax.

As of March 31,2023,the Company had cash and cash equivalents,restricted cash and short-term investments of RMB878.8 million (US$128.0 million),compared to RMB922.7 million as of December 31,2022.

Conference Call

111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday,2023 (7:30 PM Beijing Time on the same day).

Details for the conference call are as follows:

Event Title: 111,Inc. First Quarter 2023 Unaudited Financial Results

Registration Link: https://s1.c-conf.com/diamondpass/10030880-st6fye.html

All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering,each participant will receive a set of participant dial-in numbers,the Direct Event passcode,and a unique Registration ID,which can be used to join the conference call.

Please dial in 15 minutes before the call is scheduled to begin and provide the Direct Event passcode and unique Registration ID you have received upon registering to join the call.

A telephone replay of the call will be available after the conclusion of the conference call until June 22,2023 on:

Mainland China: 4001 209 217

Hong Kong: 800 901 654

United States: +1 877 642 9125

International: +61 7 3145 4057

Conference ID: 10030880

A live and archived webcast of the conference call will be available on the website at https://edge.media-server.com/mmc/p/uzvzjixt.

Use of Non-GAAP Financial Measures

In evaluating the business,the Company considers and uses non-GAAP income (loss) from operations,non-GAAP net income (loss),non-GAAP net loss attributable to ordinary shareholders,and non-GAAP loss per ADS,as supplemental measures to review and assess its operating performance. The Company defines non-GAAP income (loss) from operations as income (loss) from operations excluding share-based compensation expenses. The Company defines non-GAAP net income (loss) as net income (loss) excluding share-based compensation expenses,net of tax. The Company defines non-GAAP net loss attributable to ordinary shareholders as net loss attributable to ordinary shareholders excluding share-based compensation expenses,net of tax. The Company defines non-GAAP loss per ADS as net loss attributable to ordinary shareholders per ADS excluding share-based compensation expenses,net of tax per ADS. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP.

The Company believes that non-GAAP income (loss) from operations,and non-GAAP loss per ADS help identify underlying trends in its business that could otherwise be distorted by the effect of certain expenses that it includes in income (loss) from operations and net income (loss). Share-based compensation expenses is a non-cash expense that varies from period to period. As a result,management excludes the items from its internal operating forecasts and models. Management believes that the adjustments for share-based compensation expenses provide investors with a reasonable basis to measure the company's core operating performance,in a more meaningful comparison with the performance of other companies. The Company believes that non-GAAP income (loss) from operations,and non-GAAP loss per ADS provide useful information about its operating results,enhances the overall understanding of its past performance and future prospects and allow for greater visibility with respect to key metrics used by the management in their financial and operational decision-making.

The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools. One of the key limitations of using non-GAAP income (loss) from operations,or non-GAAP loss per ADS is that it does not reflect all items of income and expense that affect the Company's operations. Further,the non-GAAP financial measures may differ from the non-GAAP information used by other companies,including peer companies,and therefore their comparability may be limited.

The Company compensates for these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP measures,all of which should be considered when evaluating the Company's performance. The Company encourages you to review its financial information in its entirety and not rely on a single financial measure.

Reconciliation of the non-GAAP financial measures to the most comparable U.S. GAAP measures is included at the end of this press release.

Exchange Rate Information Statement

This announcement contains translations of certain RMB amounts into U.S. dollars at specified rates solely for the convenience of the reader. Unless otherwise noted,all translations from RMB to U.S. dollars are made at a rate of RMB6.8676 to US$1.00,the exchange rate set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System as of March 31,2023.

Forward-Looking Statements

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934,as amended,and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. Among other things,the Business Outlook and quotations from management in this announcement,as well as 111's strategic and operational plans,contain forward-looking statements. 111 may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission,in its annual report to shareholders,in press releases and other written materials and in oral statements made by its officers,directors or employees to third parties. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks,uncertainties and other factors,all of which are difficult to predict and many of which are beyond the Company's control. Forward-looking statements involve inherent risks,uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include,but are not limited to,uncertainties as to the Company's ability comply with extensive and evolving regulatory requirements,its ability to compete effectively in the evolving PRC general health and wellness market,its ability to manage the growth of its business and expansion plans,its ability to achieve or maintain profitability in the future,its ability to control the risks associated with its pharmaceutical retail and wholesale businesses,and the Company's ability to meet the standards necessary to maintain listing of its ADSs on the Nasdaq Global Market,including its ability to cure any non-compliance with Nasdaq's continued listing criteria. Further information regarding these and other risks,uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release,and 111 does not undertake any obligation to update any forward-looking statement as a result of new information,future events or otherwise,except as required under applicable law.

About 111,Inc.

111,Inc. (NASDAQ: YI) ("111" or the "Company") is a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China. The Company provides consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy,1 Pharmacy,and indirectly through its offline virtual pharmacy network. The Company also offers online healthcare services through its internet hospital,1 Clinic,which provides consumers with cost-effective and convenient online consultation,electronic prescription service,and patient management service. In addition,the Company's online platform,1 Medicine,serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. With the largest virtual pharmacy network in China,111 enables offline pharmacies to better serve their customers with cloud-based services. 111 also provides an omni-channel drug commercialization platform to its strategic partners,which includes services such as digital marketing,patient education,data analytics,and pricing monitoring.

For more information on 111,please visit: http://ir.111.com.cn/.

111,Inc.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands,except for share and per share data)

As of

As of

December 31,2022

March 31,2023

RMB

RMB

US$

ASSETS

Current Assets:

Cash and cash equivalents

673,669

584,544

85,116

Restricted cash

43,122

34,737

5,058

Short-term investments

205,861

259,498

37,786

Accounts receivable,net

488,875

437,288

63,674

Notes Receivable

43,332

43,364

Inventories

1,498,900

1,468,172

213,782

Prepayments and other current assets

282,066

191,720

27,916

Total current assets

3,235,825

3,019,663

439,696

Property and equipment,net

48,497

44,809

6,525

Intangible assets,net

3,267

2,871

418

Long-term investments

2,000

2,000

291

Other non-current assets

20,348

20,195

2,941

Operating lease right-of-use asset

163,877

149,275

21,736

Total Assets

3,473,814

3,238,813

471,607

LIABILITIES,MEZZANINE EQUITY AND SHAREHOLDERS' DEFICIT

Current Liabilities:

Short-term borrowings

178,990

269,852

39,293

Accounts payable

1,764,849

1,681,293

244,815

Accrued expense and other current liabilities

781,271

550,227

80,119

Total Current liabilities

2,725,110

2,501,372

364,227

Long-term operating lease liabilities

100,469

85,917

12,510

Total Liabilities

2,825,579

2,587,289

376,737

MEZZANINE EQUITY

Redeemable non-controlling interests

1,056,939

1,070,769

155,916

SHAREHOLDERS' DEFICIT

Ordinary shares Class A

31

31

5

Ordinary shares Class B

25

25

3

Treasury shares

(40,859)

(40,859)

(5,949)

Additional paid-in capital

2,977,174

3,003,037

437,276

Accumulated deficit

(3,426,556)

(3,458,343)

(503,574)

Accumulated other comprehensive income

75,586

72,706

10,587

Total shareholders' deficit

(414,599)

(423,403)

(61,652)

Non-controlling interest

5,895

4,158

606

Total Deficit

(408,704)

(419,245)

(61,046)

Total liabilities,mezzanine equity and deficit

3,607

111,Inc.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands,except for share and per share data)

For the three months ended March 31,

2022

2023

RMB

RMB

US$

Net Revenues

2,982,591

3,696,761

538,290

Operating Costs and expenses:

Cost of products sold

(2,790,056)

(3,460,548)

(503,895)

Fulfillment expenses

(94,533)

(102,650)

(14,947)

Selling and marketing expenses

(114,854)

(89,240)

(12,994)

General and administrative expenses

(47,994)

(41,317)

(6,016)

Technology expenses

(39,021)

(25,316)

(3,686)

Other operating income,net

1,716

578

84

Total Operating costs and expenses

(3,084,742)

(3,718,493)

(541,454)

Loss from operations

(102,151)

(21,732)

(3,164)

Interest income

2,043

1,949

284

Interest expense

(3,184)

(4,272)

(622)

Foreign exchange gain

391

1,634

238

Other Income,913

3,064

446

Loss before income taxes

(100,988)

(19,357)

(2,818)

Income tax expense

-

-

-

Net Loss

(100,818)

Net Loss attributable to non-controlling interest

4,477

1,400

204

Net Loss attributable to redeemable non-controlling interest

9,135

1,548

225

Adjustment attributable to redeemable non-controlling interest

(22,966)

(15,378)

(2,239)

Net Loss attributable to ordinary shareholders

(110,342)

(31,787)

(4,628)

Other comprehensive loss

Unrealized gains of available-for-sale securities,

1,298

2,135

311

Realized gains of available-for-sale debt securities

(1,335)

(1,902)

(277)

Foreign currency translation adjustments

(956)

(3,113)

(453)

Comprehensive loss

(111,335)

(34,667)

(5,047)

Loss per ADS:

Basic and diluted

(1.32)

(0.38)

(0.06)

Weighted average number of shares used in computation of loss per share

Basic and diluted

166,331,126

167,329,609

167,609

111,Inc.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

For the three months ended March 31,

2022

2023

RMB

RMB

US$

Net cash used in operating activities

(68,241)

(121,328)

(17,668)

Net cash provided by (used in) investing activities

22,859

(53,188)

(7,744)

Net cash provided by financing activities

35,278

78,497

11,430

Effect of exchange rate changes on cash and cash equivalents,and restricted cash

(731)

(1,491)

(217)

Net decrease in cash and cash equivalents,and restricted cash

(10,835)

(97,510)

(14,199)

Cash and cash equivalents,and restricted cash at the beginning of the period

760,672

716,791

104,373

Cash and cash equivalents,and restricted cash at the end of the period

749,837

619,281

90,174

111,Inc.

Unaudited Reconciliation of GAAP and Non-GAAP Results

(In thousands,

2022

2023

RMB

RMB

US$

Loss from operations

(102,151)

(21,732)

(3,164)

Add: Share-based compensation expenses

29,757

24,208

3,525

Non-GAAP income (loss) from operations

(72,394)

2,476

361

Net Loss

(100,988)

(19,357)

(2,818)

Add:Share-based compensation expenses,net of tax

29,525

Non-GAAP net Income (Loss)

(71,231)

4,851

707

Net Loss attributable to ordinary shareholders

(110,628)

Add: Share-based compensation expenses,525

Non-GAAP net Loss attributable to ordinary shareholders

(80,585)

(7,579)

(1,103)

Loss per ADS(6): Basic and diluted

(1.32)

(0.38)

(0.06)

Add: Share-based compensation expenses per ADS(6),net of tax

0.36

0.28

0.04

Non-GAAP Loss per ADS(6)

(0.96)

(0.1)

(0.02)

(6) Every oneADSs represent two Class A ordinary shares.